SOHO 2023 | Findings from the COMMANDS study and the approval of luspatercept for lower-risk MDS
Guillermo Garcia-Manero
• 9 Sep 2023
Guillermo Garcia-Manero, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on the FDA approval of luspatercept for patients with transfusion-dependent lower-risk myelodysplastic syndromes (LR-MDS) with anemia, highlighting findings from the Phase III COMMANDS study (NCT03682536). This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
